Your browser doesn't support javascript.
loading
Topical antimicrobial peptide omiganan recovers cutaneous dysbiosis but does not improve clinical symptoms in patients with mild to moderate atopic dermatitis in a phase 2 randomized controlled trial.
Niemeyer-van der Kolk, Tessa; Buters, Thomas P; Krouwels, Lara; Boltjes, Jiry; de Kam, Marieke L; van der Wall, Hein; van Alewijk, Dirk C J G; van den Munckhof, Ellen H A; Becker, Martin J; Feiss, Gary; Florencia, Edwin F; Prens, Errol P; Moerland, Matthijs; Burggraaf, Jacobus; Rissmann, Robert; van Doorn, Martijn B A.
Afiliação
  • Niemeyer-van der Kolk T; Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Center, Leiden, the Netherlands. Electronic address: tvdkolk@chdr.nl.
  • Buters TP; Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Center, Leiden, the Netherlands.
  • Krouwels L; Centre for Human Drug Research, Leiden, the Netherlands.
  • Boltjes J; Centre for Human Drug Research, Leiden, the Netherlands.
  • de Kam ML; Centre for Human Drug Research, Leiden, the Netherlands.
  • van der Wall H; Centre for Human Drug Research, Leiden, the Netherlands.
  • van Alewijk DCJG; DDL Diagnostic Laboratory, Rijswijk, the Netherlands.
  • van den Munckhof EHA; DDL Diagnostic Laboratory, Rijswijk, the Netherlands.
  • Becker MJ; Department of Medical Microbiology, Alrijne hospital, Leiden, the Netherlands.
  • Feiss G; Cutanea Life Science, Wayne, Pennsylvania.
  • Florencia EF; Department of Dermatology Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Prens EP; Department of Dermatology Erasmus Medical Centre, Rotterdam, the Netherlands.
  • Moerland M; Centre for Human Drug Research, Leiden, the Netherlands.
  • Burggraaf J; Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Center, Leiden, the Netherlands; Leiden Academic Center for Drug Research, Leiden, the Netherlands.
  • Rissmann R; Centre for Human Drug Research, Leiden, the Netherlands; Leiden University Medical Center, Leiden, the Netherlands; Leiden Academic Center for Drug Research, Leiden, the Netherlands.
  • van Doorn MBA; Centre for Human Drug Research, Leiden, the Netherlands; Department of Dermatology Erasmus Medical Centre, Rotterdam, the Netherlands.
J Am Acad Dermatol ; 86(4): 854-862, 2022 04.
Article em En | MEDLINE | ID: mdl-33010325
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Peptídeos Antimicrobianos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Dermatite Atópica / Peptídeos Antimicrobianos Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Humans Idioma: En Revista: J Am Acad Dermatol Ano de publicação: 2022 Tipo de documento: Article